Shares of Xeris Pharmaceuticals Inc (NASDAQ:XERS) have been given a consensus rating of “Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $24.50.

A number of research firms have recently weighed in on XERS. Zacks Investment Research cut Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 12th. ValuEngine cut Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. Finally, Mizuho reissued a “buy” rating and issued a $27.00 price target on shares of Xeris Pharmaceuticals in a report on Tuesday, December 4th.

Shares of NASDAQ XERS traded up $0.19 during trading on Tuesday, reaching $9.73. The company had a trading volume of 1,588,992 shares, compared to its average volume of 271,000. Xeris Pharmaceuticals has a twelve month low of $8.67 and a twelve month high of $27.98. The stock has a market cap of $259.66 million and a price-to-earnings ratio of -1.95. The company has a quick ratio of 11.59, a current ratio of 11.59 and a debt-to-equity ratio of 0.42.

Xeris Pharmaceuticals (NASDAQ:XERS) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.94) by ($0.04). The firm had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, analysts anticipate that Xeris Pharmaceuticals will post -3.28 EPS for the current year.

In other Xeris Pharmaceuticals news, major shareholder Redmile Group, Llc bought 588,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $5,880,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul R. Edick bought 30,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was acquired at an average price of $9.12 per share, with a total value of $273,600.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 620,500 shares of company stock valued at $6,178,600 and sold 159,250 shares valued at $2,452,644.

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Xeris Pharmaceuticals by 24.4% in the fourth quarter. FMR LLC now owns 2,280,968 shares of the company’s stock valued at $38,776,000 after purchasing an additional 447,937 shares during the last quarter. BlackRock Inc. increased its stake in Xeris Pharmaceuticals by 63.5% in the fourth quarter. BlackRock Inc. now owns 645,035 shares of the company’s stock valued at $10,966,000 after purchasing an additional 250,619 shares during the last quarter. Vanguard Group Inc. increased its stake in Xeris Pharmaceuticals by 920.3% in the third quarter. Vanguard Group Inc. now owns 255,064 shares of the company’s stock valued at $4,484,000 after purchasing an additional 230,064 shares during the last quarter. Vanguard Group Inc increased its stake in Xeris Pharmaceuticals by 920.3% in the third quarter. Vanguard Group Inc now owns 255,064 shares of the company’s stock valued at $4,484,000 after purchasing an additional 230,064 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Xeris Pharmaceuticals by 23.0% in the fourth quarter. Geode Capital Management LLC now owns 82,692 shares of the company’s stock valued at $1,405,000 after purchasing an additional 15,459 shares during the last quarter. Hedge funds and other institutional investors own 51.68% of the company’s stock.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

See Also: How prevalent are 12b-1 fees?

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.